DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 117.3% from a year ago
Other current liabilities stood at $741K at the end of Q1 FY2026, up 117.3% from a year earlier and down 46.3% from the prior quarter. Over 3 fiscal years it compounded at +27.4% a year.
Context
- Other current liabilities amounted to 1.4% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +117.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.38M USD
- Year-over-year change
- +30.2%
- 4-year CAGR
- +29.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.38M | +30.2% |
| FY2024 | 2024-12-31 | 1.06M | +38.4% |
| FY2023 | 2023-12-31 | 766K | +14.8% |
| FY2022 | 2022-12-31 | 667K | +37.8% |
| FY2021 | 2021-12-31 | 484K | — |
Other Current Liabilities vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 other current liabilities of $741K is the 5th highest of the 7 companies compared; the peer median is $5.08M.
- Its year-over-year change of +117.3% is the 2nd highest of 7, against a peer median of +10.7%.
- Other current liabilities amounts to 1.4% of total assets for DMAC, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $148.51M | +213.4% | +24.6% | 41.0% | |
| Mar 2026 | $21.7M | +104.9% | — | 33.7% | |
| Mar 2026 | $5.42M | -25.5% | +13.2% | 1.3% | |
| Mar 2026 | $4.74M | -6.6% | +52.2% | 1.6% | |
| Mar 2026 | $741K | +117.3% | +27.4% | 1.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $714K | +28.0% | +179.7% | 0.2% |
| Jun 2026 | $0 | -100.0% | +46.1% | 0.0% | |
| Peer median (excluding DMAC) | $5.08M | +10.7% | +46.1% | 1.5% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.